Skip to content

Viking Therapeutics VKTX Net investment gains (losses)

Net investment gains (losses) at other companies

Repligen logo
RepligenRGEN
$0
Main Street Capital logo
Main Street CapitalMAIN
$17.97M+161%
BankUnited logo
BankUnitedBKU
$3.29M+249%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0
First Commonwealth Financial logo
First Commonwealth FinancialFCF
$0-100%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$21K+333%

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.

The official record: Viking Therapeutics’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's net investment gains (losses).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's net investment gains (losses)?
Viking Therapeutics (VKTX) reported net investment gains (losses) of $13.75K in Q4 2025.
How has Viking Therapeutics's net investment gains (losses) changed year-over-year?
Viking Therapeutics's net investment gains (losses) increased by 1275.0% year-over-year, from $1K to $13.75K.
What does net investment gains (losses) mean?
Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.